Aspire Biopharma Reports First Revenue of $1,941 in Q3 2025 Amid Significant Losses

Aspire Biopharma Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a net revenue of $1,941, marking the company's first revenue generation since its inception. This figure represents a significant increase compared to the same period in 2024, when the company reported no revenue. The cost of goods sold for the quarter was $1,057, resulting in a gross profit of $884. However, the company incurred a net loss of $1,850,493 for the quarter, a substantial increase from the net loss of $216,269 reported in the third quarter of 2024.

For the nine months ending September 30, 2025, Aspire's total revenue also stood at $1,941, with a gross profit of $884. The company's operating expenses surged to $17,502,751, compared to $543,149 in the same period last year. This increase was primarily driven by a rise in general and administrative expenses, which totaled $15,982,233, largely due to stock-based compensation and professional services. The net loss for the nine-month period reached $19,773,114, compared to a loss of $544,162 in the prior year.

Aspire's balance sheet reflects a significant increase in total assets, which rose to $2,403,129 as of September 30, 2025, compared to $147,989 at the end of 2024. This increase is attributed to the company's reverse acquisition of Aspire Biopharma, Inc. in February 2025, which also led to a substantial rise in current liabilities, totaling $13,860,506. The company's accumulated deficit has grown to $22,550,347, indicating ongoing financial challenges.

Strategically, Aspire has focused on developing its sublingual delivery technology for known drugs, particularly its high-dose aspirin product. The company has completed clinical trials that demonstrated faster absorption rates compared to traditional oral aspirin, with plans to submit a New Drug Application (NDA) to the FDA in early 2026. Additionally, Aspire has entered into various financing agreements, including a Securities Purchase Agreement that raised $3,750,000 and an equity line of credit agreement allowing for the potential sale of up to $100 million in common stock.

Looking ahead, Aspire's management has expressed concerns regarding the company's liquidity, noting a working capital deficit of $11,457,377 as of September 30, 2025. The company plans to raise additional capital to support its operations and product development, but there is uncertainty regarding its ability to secure financing on favorable terms. The management has indicated that the company's financial condition raises substantial doubt about its ability to continue as a going concern over the next twelve months.